FDA Panel Endorses BPC-157, Boosting Hims & Hers Health (HIMS)
Shares of Hims & Hers Health rose over 10% after an FDA advisory panel approved the inclusion of peptide BPC-157 in a list for compounding pharmacies. This decision could expand potential applications and market opportunities for the company.
Tickers: $HIMS
Topics: compounding_pharmacies pharmaceuticals stock_movement